Denali Therapeutics (DNLI) - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US24823R1059

(NASDAQ:DNLI Stock) Denali Therapeutics Inc., a biopharmaceutical company, developing a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases. It pursues new treatments by assessing genetically validated targets, engineering delivery across the blood-brain barrier, and guiding development through biomarkers that demonstrate target and pathway engagement. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; and DNL343 eIF2B Activator program for amyotrophic lateral sclerosis. The company's other programs comprise SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. Web URL:

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Denali Therapeutics (DNLI) - Stock Price & Dividends

DNLI Stock Overview

Market Cap in USD 2,326m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2017-12-08

DNLI Stock Ratings

Fundamental -6.57
Dividend -
Growth 5y -1.59
Rel. Performance vs Sector -6.25
Analysts 4.53
Fair Price Total Ret. 14.62
Fair Price DCF -

DNLI Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

DNLI Growth Ratios

Growth 12m -34.66%
Growth Correlation 12m -57%
Growth Correlation 3m -42%
CAGR 5y -5.11%
CAGR / Mean Drawdown -0.11
Sharpe Ratio 12m -0.73
Alpha vs SP500 12m -77.46
Beta vs SP500 5y weekly 1.51
CAPM 9.43%
Average Daily Range 2m 4.64%
Regime Oscillator 55.80
Volatility GJR Garch 1y 71.46%
Price / SMA 50 -9.9%
Price / SMA 200 -26.77%
Current Volume 1076.7k
Average Volume 20d 1201.5k

External Links for DNLI Stock

Wall Street JournalBenzingaYahoo Finance
X (Twitter)Stocktwits
Fund Manager Positions
What is the price of DNLI stocks?
As of February 24, 2024, the stock is trading at USD 16.93 with a total of 1,076,707 shares traded.
Over the past week, the price has changed by -0.53%, over one month by -0.99%, over three months by -8.04% and over the past year by -36.73%.
Why is DNLI stock down?
Check with which Index or Commodity DNLI has the highest Correlation, do they have a common driver?
Review the Fundamentals to find weaknesses (Debt, low returns). Check the Performance of the Peer-Group to find out, if the entire sector is under pressure.
Period Return DNLI Return S&P 500
1 Month -0.99% 4.74%
3 Months -8.04% 11.99%
12 Months -36.73% 28.68%
What is the forecast for DNLI stock price target?
According to ValueRays Forecast Model, DNLI Denali Therapeutics will be worth about 16.2 in February 2025. The stock is currently trading at 16.93. This means that the stock has a potential downside of -4.25%.
Issuer Forecast Upside
Wallstreet Target Price 46.4 174.0%
Analysts Target Price 55.6 228.4%
ValueRay Target Price 16.2 -4.3%